



NS5A-P32 deletion as an obstacle to DAA therapy

1
2 **A challenge to overcome: NS5A-P32 deletion in DAA-based therapy for HCV**
3
4 Sato and Uraoka. NS5A-P32 deletion as an obstacle to DAA therapy
5
6 **Ken Sato, Toshio Uraoka**
7
8 **Abstract**
9 Interferon (IFN)-based therapy for hepatitis C virus (HCV) infection has
10 recently been replaced by IFN-free direct-acting antiviral (DAA)-based therapy,
11 which has been established as a 1st line therapy with high efficacy and
12 tolerability due to its reasonable safety profile. Resistance-associated
13 substitutions (RASs) have been a weakness of DAA-based therapy.
14 For example, combination therapy with daclatasvir and asunaprevir
15 (DCV/ ASV) is less effective for HCV genotype 1-infected patients with Y93H as
16 a non-structural (NS)5A RAS. However, the problem regarding RASs has been
17 gradually overcome with the advent of recently developed DAAs, such as
18 sofosbuvir-based regimens or combination therapy with glecaprevir and
19 pibrentasvir. Despite the high efficiency of DAA-based therapy, some cases fail
20 to achieve viral eradication. P32 deletion, an NS5A RAS, has been gradually
21 noticed in patients with DCV/ ASV failure. P32 deletion has been sporadically
22 reported and the prevalence of this RAS has been considered to be low in

Match Overview

1 **Crossref** 31 words
Yuji Teraoka, Takuro Uchida, Michio Imamura, Mitsutaka Osawa et al. "Prevalence of NS5A resistance associated varia" 1%



All

News

Images

Videos

Shopping

More

Settings

Tools

About 2,080 results (0.63 seconds)

Hitomi Sezaki's scientific contributions | Toranomon Hospital, Tokyo ...

https://www.researchgate.net/scientific-contributions/38347977_Hitomi_Sezaki

Direct-acting antiviral (**DAA**) **treatment** produced a sustained virological response 12 (SVR12). ... of direct-acting antivirals in chronic **hepatitis C** patients with **NS5A-P32 deletion** Abstract: A prospective study **based** on serial liver biopsies was performed to Some of these adverse effects can be **overcome** and reduced.

Mariko Kobayashi's scientific contributions | Toranomon Hospital ...

https://www.researchgate.net/scientific-contributions/38457468_Mariko_Kobayashi

Direct-acting antiviral (**DAA**) **treatment** produced a sustained virological response 12 ... 4 of 6 patients with **P32 deletion** received retreatment of DAAs, and could not ... with **HCV** genotype 1-related chronic liver disease treated with either **NS5A** (TDF)-**based** rescue **therapy** in patients with chronic **hepatitis B** refractory to ...

Successes and Challenges on the Road to Cure Hepatitis C - PLOS

journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1004854 ▼

by SM Horner - 2015 - Cited by 23 - Related articles

Jun 18, 2015 - While the successes attributable to **DAA** combination **therapies** will be many, ... several of the greatest successes and future **challenges** in **HCV** therapeutics today. Combining simeprevir with the potent **DAA** sofosbuvir appears to **overcome** this ... Baseline **NS5A** polymorphisms that confer resistance are ...

Missing: p32 deletion

[全部](#)[图片](#)[视频](#)[新闻](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 6 条结果 (用时 0.47 秒)

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.

<https://www.ncbi.nlm.nih.gov/pubmed/26083155> - [翻译此页](#)

作者: JA Gutierrez - 2015 - 被引用次数: 64 - 相关文章

2015年6月17日 - Interferon-free, **direct-acting antiviral therapy** for chronic hepatitis C. ... Gone are interferon-based **therapy** and its associated tolerability **challenges**, inadequate response rates and ... **Antiviral Agents**; Enzyme Inhibitors; NS-5 protein, **hepatitis C virus**; NS3 protein, **hepatitis C virus**; Viral **Nonstructural Proteins**.

缺少字词: overcome p32 deletion

Nonstructural protein 5A/P32 deletion after failure of ledipasvir ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29425404> - [翻译此页](#)

2018年5月14日 - **Nonstructural protein 5A/P32 deletion** after failure of ledipasvir/sofosbuvir in **hepatitis C virus** genotype 1b infection. Doi A(1), Hikita H(1), ...

缺少字词: challenge overcome direct acting antiviral based therapy

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/27080301> - [翻译此页](#)

作者: JM Pawlotsky - 2016 - 被引用次数: 201 - 相关文章

2016年4月11日 - **Treatment of hepatitis C virus** (HCV) infection has progressed considerably with the approval of interferon-free, **direct-acting antiviral** (DAA)-based combination **therapies**. Although ... **Antiviral Agents**; NS-5 protein, **hepatitis C virus**; NS3 protein, **hepatitis C virus**; Protease Inhibitors; Viral **Nonstructural Proteins**.

缺少字词: challenge overcome p32 deletion

Direct-acting antiviral treatment in adults infected with hepatitis C virus ...

<https://www.ncbi.nlm.nih.gov/pubmed/26967675> - [翻译此页](#)

作者: A De Monte - 2016 - 被引用次数: 88 - 相关文章

2016年3月3日 - **Direct-acting antiviral treatment** in adults infected with **hepatitis C virus**: Reactivation of hepatitis B virus coinfection as a further **challenge**. ... Cua E(2), Naqvi A(2), Mondain V(2), Cottalorda J(1), Ollier L(4), Giordanengo V(5). ... Several inhibitors of viral **nonstructural proteins** (NS3/4A protease, NS5A and ...

缺少字词: overcome p32 deletion

[全部](#)[图片](#)[视频](#)[新闻](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 6 条结果 (用时 0.47 秒)

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.

<https://www.ncbi.nlm.nih.gov/pubmed/26083155> - 翻译此页

作者: JA Gutierrez - 2015 - 被引用次数: 64 - 相关文章

2015年6月17日 - Interferon-free, **direct-acting antiviral therapy** for chronic hepatitis C. ... Gone are interferon-based **therapy** and its associated tolerability **challenges**, inadequate response rates and ... **Antiviral Agents**; Enzyme Inhibitors; NS-5 protein, **hepatitis C virus**; NS3 protein, **hepatitis C virus**; Viral **Nonstructural Proteins**.

缺少字词: overcome p32 deletion

Nonstructural protein 5A/P32 deletion after failure of ledipasvir ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29425404> - 翻译此页

2018年5月14日 - **Nonstructural protein 5A/P32 deletion** after failure of ledipasvir/sofosbuvir in **hepatitis C virus** genotype 1b infection. Doi A(1), Hikita H(1), ...

缺少字词: challenge overcome direct acting antiviral based therapy

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/27080301> - 翻译此页

作者: JM Pawlotsky - 2016 - 被引用次数: 201 - 相关文章

2016年4月11日 - **Treatment of hepatitis C virus** (HCV) infection has progressed considerably with the approval of interferon-free, **direct-acting antiviral** (DAA)-based combination **therapies**. Although ... **Antiviral Agents**; NS-5 protein, **hepatitis C virus**; NS3 protein, **hepatitis C virus**; Protease Inhibitors; Viral **Nonstructural Proteins**.

缺少字词: challenge overcome p32 deletion

Direct-acting antiviral treatment in adults infected with hepatitis C virus ...

<https://www.ncbi.nlm.nih.gov/pubmed/26967675> - 翻译此页

作者: A De Monte - 2016 - 被引用次数: 88 - 相关文章

2016年3月3日 - **Direct-acting antiviral treatment** in adults infected with **hepatitis C virus**: Reactivation of hepatitis B virus coinfection as a further **challenge**. ... Cua E(2), Naqvi A(2), Mondain V(2), Cottalorda J(1), Ollier L(4), Giordanengo V(5). ... Several inhibitors of viral **nonstructural proteins** (NS3/4A protease, NS5A and ...

缺少字词: overcome p32 deletion